文献速递胸部肿瘤

Vebreltinib治疗MET扩增驱动晚期非小细胞肺癌:KUNPENG单臂多队列2期研究

Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study.
PubMed 文献 · Lancet Oncol · 2025-12-06

KUNPENG研究是在中国17家医院开展的多中心、多队列、单臂2期试验,评估Vebreltinib在MET扩增驱动晚期NSCLC患者中的抗肿瘤活性和安全性。

要点

  • ≥3级治疗相关不良事件发生率为31%,以肝功能异常为主。
  • 研究为单臂设计,需进一步研究验证。

核心结论

  • Vebreltinib在既往接受过化疗或未经化疗的MET扩增驱动晚期NSCLC患者中显示出抗肿瘤活性。

研究设计与样本

  • KUNPENG为在中国17家医院开展的多中心、多队列、单臂2期试验。
  • 纳入MET抑制剂初治、年龄≥18岁、MET扩增驱动(基因拷贝数≥6)的局部晚期或转移性NSCLC患者。
  • 患者接受Vebreltinib 200 mg口服每日两次直至疾病进展或不可耐受毒性。
  • 主要终点为全分析集中由盲态独立评审委员会评估的客观缓解率。
  • 当前分析纳入队列2和3的86例患者(化疗经治30例、未经化疗56例)。

主要发现

  • ≥3级治疗相关不良事件发生率为31%(27/86),主要为研究者报告的肝功能异常(8例[9%])。
  • 治疗相关严重不良事件报告16例(19%)。
  • 11例治疗中出现的不良事件导致死亡,其中1例死于肝功能异常,可能与Vebreltinib治疗相关。

临床怎么用

  • 对于MET扩增驱动(基因拷贝数≥6)的晚期NSCLC,Vebreltinib可作为既往化疗后或不适/拒绝化疗患者的潜在治疗选择。
  • 治疗期间需密切监测肝功能等不良事件。

局限性

  • 研究为单臂设计,无对照。
  • 样本量有限,当前分析仅纳入86例患者。
  • 研究因入组缓慢修订合并队列2和3,并提前终止入组。
  • 所有患者均为中国人群,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: MET amplification is recognised as a de novo driver alteration in non-small-cell lung cancer (NSCLC) but treatment responses with existing MET inhibitors remain largely unsatisfactory. We aimed to investigate the antitumour activity and safety of vebreltinib, a potent and highly selective MET inhibitor, in patients with MET amplification-driven NSCLC. METHODS: KUNPENG was a multicentre, multi-cohort, single-arm, phase 2 trial conducted across 17 hospitals in China, in patients with locally advanced or metastatic NSCLC with MET dysregulation. Patients were eligible if they were MET inhibitor-naive, aged 18 years or older with MET amplification-driven NSCLC (gene copy number of six or higher), and progressed after previous standard chemotherapy or were ineligible for chemotherapy (cohort 2) or refused chemotherapy (cohort 3). Patients received 200 mg vebreltinib orally twice daily until disease progression or intolerable toxicity. The primary endpoint was the objective response rate, assessed by a masked independent review committee in the full analysis set. The study was amended to merge cohorts 2 and 3 due to slow accrual and was closed to enrolment on Nov 14, 2023. This trial is registered with ClinicalTrials.gov (NCT04258033). FINDINGS: Between Jan 17, 2020, and Nov 14, 2023, 145 patients were enrolled; of these, 86 patients (30 chemotherapy-treated and 56 untreated) from cohorts 2 and 3 were included in the current analysis. The median age was 65 years (range 48-82; IQR 59-71), 77 (90%) patients were male, and nine (10%) were female. All patients were Chinese. 42 patients had partial response, resulting in an objective response rate of 48·8% (42 of 86; 95% CI 38·3-59·4) per masked independent review committee. The median follow-up was 18·6 months (IQR 15·7-37·3). The incidence of grade 3 or worse treatment-related adverse events was 31% (27 of 86), predominantly abnormal liver function terms reported by the investigators (eight [9%]). Serious adverse events related to treatment were reported by 16 (19%) patients. 11 treatment-emergent adverse events leading to death occurred, of which one patient died of abnormal liver function, which was possibly related to vebreltinib treatment. INTERPRETATION: Vebreltinib showed antitumour activity in patients with MET amplification-driven advanced NSCLC who had previously received chemotherapy or were chemotherapy-naive. Further research is needed to validate these findings. FUNDING: Beijing Pearl Biotechnology and Avistone Biotechnology.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Wu YL, Yao Y, Yang JJ, et al. Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study. Lancet Oncol. 2025. PMID: 41365311. doi:10.1016/S1470-2045(25)00594-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。